諾誠健華(09969.HK)抑製劑ICP-723獲批准於美國開展臨床研究
諾誠健華(09969.HK)公布,自主研發的第二代泛TRK小分子抑製劑ICP-723,獲美國食品藥品監督管理局(FDA)批准開展臨床研究。
此次臨床試驗將主要評估ICP-723在實體瘤患者中的安全性、耐受性及藥代動力學特性,並評價ICP-723對NTRK融合基因陽性癌症的抗腫瘤療效。
ICP-723是諾誠健華在全球擁有自主知識產權的1類創新藥,用於治療攜帶NTRK融合基因的晚期或轉移性實體瘤,包括乳腺癌、結直腸癌、肺癌、甲狀腺癌等,以及對第一代TRK抑製劑產生耐藥的患者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.